Edaravone is the active ingredient in a treatment that is sold under the product name RADICAVA®. This medication is available to people with amyotrophic lateral sclerosis (ALS) who reside in Japan, South Korea, USA, Canada, Switzerland, China, Indonesia, Thailand and Malaysia. On the 15th of February 2023, the Therapeutic Goods Administration (TGA) in Australia approved RADICAVA® for the treatment of ALS in Australia.
Teva Pharma Australia, who have commercialised the product for use in Australia, has applied to the Pharmaceutical Benefits Advisory Committee (PBAC) to have RADICAVA® listed on the Pharmaceutical Benefit Scheme (PBS) for eligible people with ALS in Australia. They have stated RADICAVA® will be available in Australia only after it is listed on the Pharmaceutical Benefits Scheme (PBS).
As part of the application process, the PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. Public consultation is now open for the November 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda which will include the consideration of Edaravone (RADICAVA®) for listing on the Pharmaceutical Benefits Scheme (PBS). This therefore provides an avenue for those with lived experience of MND to provide direct input into the process of consideration of Edaravone (RADICAVA®) for listing on the Pharmaceutical Benefits Scheme (PBS).
The consultation is an online survey process and the consultation portal can be found online here. We encourage you to get involved in this process if you have Lived Experience of MND.
Submissions will be accepted until 20 September 2023. For more information, you can see the MND Australia submission to the PBAC.
